- Home
- NVCR
NVCR
NovoCure Limited
as 12-23-2024 4:00pm EST
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
| Founded: | 2000 | Country: | Jersey |
| Employees: | N/A | City: | ST. HELIER |
| Market Cap: | 3.0B | IPO Year: | 2015 |
| Target Price: | $33.40 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.70 - $34.13 | Next Earning Date: | 10-30-2024 |
| Revenue: | $577,738,000 | Revenue Growth: | 14.63% |
| Revenue Growth (this year): | 19.13% | Revenue Growth (next year): | 5.38% |
Stock Insider Trading Activity of NovoCure Limited (NVCR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Paravasthu Mukund | NVCR | Chief Operating Officer | Nov 2 '24 | Sell | $16.69 | 44 | $734.18 | 3,459 | |
| Leonard Frank X | NVCR | EVP, Pres., Novocure Oncology | Nov 1 '24 | Sell | $15.94 | 598 | $9,530.74 | 161,236 | |
| Paravasthu Mukund | NVCR | Chief Operating Officer | Nov 1 '24 | Sell | $15.88 | 160 | $2,540.42 | 3,459 | |
| Puri Michal Nath | NVCR | Chief Human Resources Officer | Oct 31 '24 | Sell | $15.79 | 810 | $12,791.68 | 110,093 |
Latest NovoCure Limited News
NVCR Breaking Stock News: Dive into NVCR Ticker-Specific Updates for Smart Investing
TipRanks
10 days ago
Novocure price target raised to $42 from $28 at Piper Sandler
Motley Fool
18 days ago
Why NovoCure Stock Was Winning Big This Week
Motley Fool
19 days ago
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
Investor's Business Daily
20 days ago
Novocure Stock Earns 96 RS Rating
Zacks
21 days ago
NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals
TipRanks
21 days ago
Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint
Investor's Business Daily
21 days ago
Novocure Launches 49% After Pancreatic Cancer Treatment Succeeds
Medical Device Network
21 days ago
Novocure seeks approval after pancreatic cancer wearable scores at Phase III
Compare NVCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVCR NovoCure Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.